Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H A Peters

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 1995
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancerJ Grøndahl-Hansen, H A Peters, W L van Putten, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 20, 1990
Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studiesJ G Klijn, B Setyono-Han, G H Bakker, et al.
Cancer Research|July 17, 2001
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancerJ A Foekens, H A Peters, N Grebenchtchikov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Prognostic significance of cathepsins B and L in primary human breast cancerJ A Foekens, J Kos, H A Peters, et al.
British Journal of Cancer|July 2, 1999
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancerJ H de Witte, C G Sweep, J G Klijn, et al.
British Journal of Cancer|March 31, 1999
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patientsJ H de Witte, C G Sweep, J G Klijn, et al.
Cancer Research|February 17, 2000
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patientsJ A Foekens, H A Peters, M P Look, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 1995
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancerJ Grøndahl-Hansen, H A Peters, W L van Putten, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 20, 1990
Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studiesJ G Klijn, B Setyono-Han, G H Bakker, et al.
Cancer Research|July 17, 2001
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancerJ A Foekens, H A Peters, N Grebenchtchikov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Prognostic significance of cathepsins B and L in primary human breast cancerJ A Foekens, J Kos, H A Peters, et al.
British Journal of Cancer|July 2, 1999
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancerJ H de Witte, C G Sweep, J G Klijn, et al.
British Journal of Cancer|March 31, 1999
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patientsJ H de Witte, C G Sweep, J G Klijn, et al.
Cancer Research|February 17, 2000
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patientsJ A Foekens, H A Peters, M P Look, et al.
Pageof 7